US-Cuba Administrative Supplement to the Viral Immunity and Vaccination (VIVA) Human Immunology Project Consortium

SUMMARY Viral Immunity and Vaccination (VIVA) Human Immunology Project Consortium (HIPC) will carry out a comprehensive program for assessing the dynamic human immune responses to vaccination. The VIVA HIPC will leverage recent advances in human immune profiling methods to characterize the diverse states of the human innate immune system before and after vaccination against these infectious diseases using novel immune phenotyping and genomics strategies that generate data and tools to be used for downstream data analysis and functional investigations. We will generate human immune profiles and signatures for vaccinations against SARS-CoV-2 (Project 1), seasonal influenza (Project 2) and dengue viruses (Project 3). We will use holistic approaches to provide cutting-edge standardized and qualified `omics' assays to assess cellular and serological Immune responses to vaccinations, genomics/transcriptomics, including scRNAseq, CITEseq and spatial tissue transcriptomics, and experimental vaccinations in primary human tonsillar histocultures in Projects 1, 2 and 3. We will perform data mining, bioinformatics analyses across data sets, and modeling for integration of the `omics' datasets to identify the network components and infer their interactions and correlations important for outcomes. The VIVA HIPC will make the data available for use by the research community and provide the analyses and immune profiles generated to the scientific community. We will couple our local data infrastructure to ImmPort to ensure full and timely release of clinical, sample, and experimental meta-data in synchrony with genomic data releases to standard data repositories. The multi-disciplinary team of investigators with complementary expertise in viral immunology, viral pathogenesis, vaccinology, genomics and data analysis, will ensure the success of the VIVA program.